Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Yuanxi Medicine Corp. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners, which indicates that each case is being reviewed by a different official. The portfolio is active in 2 distinct art units, suggesting that the company's research in Biotechnology & Pharmaceuticals is being evaluated under different technical classifications. This distribution across 2 art units may require the legal team to adapt their arguments to the specific requirements of each unit.
RAMACHANDRAN, UMAMAHESWARI is the busiest examiner for this portfolio, currently overseeing 1 of the pending office actions. Since there are 2 pending office actions in total, this examiner is responsible for a portion of the company's current workload in this sector. The involvement of 2 distinct examiners across 2 art units for only 2 pending actions shows a fragmented prosecution landscape for a small portfolio. Practitioners should prepare for different examiner styles from both RAMACHANDRAN, UMAMAHESWARI and the other assigned official. Successfully resolving these 2 pending office actions will depend on navigating the specific technical nuances of the different art units involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAMACHANDRAN, UMAMAHESWARI | 1 | 54.8% | +53.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18728828 | USE OF BENZISOSELENAZOLE COMPOUND IN PREPERATION OF DRUG FOR TREATMENT OF SPINAGLIOMA | RAMACHANDRAN, UMAMAHESWARI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18728828 | USE OF BENZISOSELENAZOLE COMPOUND IN PREPERATION OF DRUG FOR TREATMENT OF SPINAGLIOMA | RAMACHANDRAN, UMAMAHESWARI | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18728828 | USE OF BENZISOSELENAZOLE COMPOUND IN PREPERATION OF DRUG FOR TREATMENT OF SPINAGLIOMA | RAMACHANDRAN, UMAMAHESWARI | 1627 | §102§103 | Non-Final OA | — | Pending | Jul 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Yuanxi Medicine Corp. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Umamaheswari Ramachandran has the most, with 1 of Shanghai Yuanxi Medicine Corp.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
